B2M and neoplasm: ,193,194 Loss-of-function mutations or LOH195 of MHC-I and beta-2-microglobulin (B2M) are frequently enriched across tumours181,196 and the adaptive immune system promotes evolutionary selection by killing tumour cells that present immunogenic antigens.